- Labelled indications: adjunct to surgery, radiation or chemotherapy for adenocarcinoma of the stomach and colon; topical therapy for superficial transitional cell carcinoma of urinary bladder
- Unlabeled indications: topical therapy for esophageal strictures; topical therapy in ophthalmologic procedures/surgery
THIS MEDICATION IS TO BE ADMINISTERED BY A CHEMO-TRAINED NURSE. IF THE NURSE IS NOT CHEMO-TRAINED, THEY ARE TO CONTACT THE UNIT NURSE EDUCATOR OR ADVANCED PRACTICE NURSE.
- Available as 5 mg and 20 mg vials
- Store at room temperature, protect from light
- Reconstitute 5 mg vial with 10 ml sterile water for injection to get 0.5 mg/mL solution
- Reconstitute 20 mg vial with 40 mL sterile water for injection to get 0.5 mg/mL solution
- Reconstituted solution stable 6 hours at room temperature or 72 hours refrigerated
-Solutions Compatible: 0.45% NaCl and 0.9% NaCl, ringer's lactate
-Additives/Above Cassette Compatible: dexamethasone, heparin, hydrocortisone, furosemide, metoclopramide
-Y-site Compatible: furosemide, granisetron, heparin, leucovorin, metoclopramide, ondansetron
Incompatible: dextrose solutions
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
| SC | NO |
| IM | NO |
| IV Direct | NO |
| IV Intermittent Infusion | YES - over 15-30 minutes via freely-running saline solution Consider using a central venous catheter |
| IV Continuous Infusion | NO |
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
- 20 mg/m2IV as a single dose
- 2 mg/m2/day IV for 5 days, drug-free interval for 2 days then repeat (therefore total dose of 20 mg/m2given over 10 days)
- Intravesicular administration: 20 – 40 mg intravesically retained for 2 hours then drained, once weekly for 8 weeks
- Mitomycin solution diluted to 0.1-0.3 mg/mL applied locally for esophageal strictures and ophthalmologic procedures
Dosage adjustment in renal/hepatic impairment
Renal impairment: administer 75% of dose with creatinine clearance <10 mL/min
Hepatic impairment: No information
- Vesicant. If extravasation occurs, see Treatment of Infiltrated Vesicant or Irritant Drugs Guidelines on CHEOnet.
- Common: fever,nausea,vomiting (considered to have low emetogenic potential), myelosuppression, thrombotic thrombocytopenia purpura, hemolytic uremia syndrome, dematitis, palmar rash with desquamation
- Occasional: alopecia, mucositis, increased serum creatinine
- Rare: dyspnea, heart failure, hepatic sinusoidal obstruction syndrome, interstitial fibrosis, pulmonary infiltrates, rash, renal failure
- To prevent extravasation -administer via freely running saline solution(preferably using a central venous catheter)
- Monitoring: CBC with differential, serum creatinine
- When used intravesically may cause bladder fibrosis/contraction